Senti Biosciences, Inc. (the 'Company') completed a holding company reorganization on April 24, 2026, under Section 251(g) of the Delaware General Corporation Law (DGCL). Senti Biosciences Holdings, Inc. ('Senti Biosciences Holdings') is now the successor issuer, with Senti Biosciences, Inc. becoming a wholly-owned subsidiary of Senti Holdings, Inc., which is itself a wholly-owned subsidiary of Senti Biosciences Holdings. Each outstanding share of Senti Biosciences common stock was automatically converted into one share of Senti Biosciences Holdings common stock, retaining identical rights, powers, and preferences. Outstanding warrants to purchase Senti Biosciences common stock were converted into rights to purchase an equal number of Senti Biosciences Holdings common stock. The reorganization is intended to be a tax-free transaction for U.S. federal income tax purposes, meaning shareholders should not recognize gain or loss. Senti Biosciences Holdings common stock continues to trade on the Nasdaq Capital Market under the ticker symbol SNTI, with a new CUSIP number (816944 102). Senti Biosciences Holdings assumed all existing equity plans, indemnification agreements, sales agreements, investor rights and lock-up agreements, note subscription agreements, and registration rights agreements from Senti Biosciences. The consolidated assets, businesses, and operations of Senti Biosciences Holdings are not materially different from those of Senti Biosciences prior to the reorganization. Senti Biosciences will be delisted from the Nasdaq Capital Market and deregistered under the Exchange Act; Senti Biosciences Holdings will now make SEC filings under Senti Biosciences' prior CIK.